Successful Treatment of the Anemia of Rheumatoid Arthritis with Subcutaneously Administered Recombinant Human Erythropoietin:Slower response in patients with more severe inflammation

Publisher Website
Google Scholar
Abstract
We performed a 24-week open clinical study in which 12 patients with rheumatoid arthritis (RA) and anemia (mean hemoglobín (Hb) value 102 g/l, range 90–109 g/l) were treated with recombinant human erythropoietin (rHuEPO). rHuEPO was given as a subcutaneous injection twice weekly with an initial dose of 300 U/kg/week. Nine of the II patients who completed the study responded with an increase in Hb value of 15 g/l or more within 3 to 17 weeks. Three months after treatment the Hb levels were significantly lower than the highest Hb levels (p < 0.0001). There was an inverse correlation between the response rate md the mean scrum concentrations of C-reactive protein and serum amyloid A protein (p <0.001 and p <0.003. respectively). We conclude that rHuEPO can correct anemia in patients with RA. but the response seems to be adversely influenced by the inflammatory activity of the disease.

This publication has 19 references indexed in Scilit: